{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:26Z","timestamp":1790912486937,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127558","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T17:57:16Z","timestamp":1753984636000},"page":"127558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine"],"prefix":"10.1016","volume":"62","author":[{"given":"Tarek","family":"El Hindi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvaporn","family":"Anugulruengkitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keswadee","family":"Lapphra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriengsak","family":"Limkittikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auchara","family":"Tangsathapornpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Galindo-Tsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Roubinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Schuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibadas","family":"Biswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Folschweiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127558_bb0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127558_bb0010","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127558_bb0015","first-page":"37","volume":"3","author":"Jing","year":"2019","journal-title":"Dengue epidemiology Global Health J"},{"key":"10.1016\/j.vaccine.2025.127558_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100712","article-title":"Global, regional, and national dengue burden from 1990 to 2017:A systematic analysis based on the global burden of disease study 2017","volume":"32","author":"Zeng","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2025.127558_bb0025","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2025.127558_bb0030","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127558_bb0035","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127558_bb0040","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127558_bb0045","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127558_bb0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127558_bb0055","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127558_bb0060","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127558_bb0065","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127558_bb0070","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127558_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127558_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011124","article-title":"Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: a phase 3 randomized, controlled study","volume":"17","author":"Tricou","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127558_bb0085","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.vaccine.2023.01.007","article-title":"A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country","volume":"41","author":"Tricou","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127558_bb0090","doi-asserted-by":"crossref","DOI":"10.26633\/RPSP.2021.67","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naive adolescents in Mexico City","volume":"45","author":"Biswal","year":"2021","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.vaccine.2025.127558_bb0095","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1016\/j.vaccine.2023.09.049","article-title":"Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): a randomized placebo-controlled trial in US adults","volume":"41","author":"Tricou","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127558_bb0100","author":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2025.127558_bb0105","author":"Pharmaceutical Technology"},{"key":"10.1016\/j.vaccine.2025.127558_bb0110","author":"Pharmaceutical Technology"},{"key":"10.1016\/j.vaccine.2025.127558_bb0115","unstructured":"Precision Vaccinations. QDENGA Dengue Vaccine. 2024 https:\/\/www.precisionvaccinations.com\/vaccines\/qdenga-dengue-vaccine#:\u223c:text=As%20of%20January%202024%2C%20QDENGA,Takeda's%20revenues%20in%20FY%202023; [accessed March 1, 2024]."},{"key":"10.1016\/j.vaccine.2025.127558_bb0120","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127558_bb0125","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127558_bb0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(24)00046-1","article-title":"Brazil to start widespread dengue vaccinations","volume":"403","author":"Alves","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127558_bb0135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jiph.2023.02.014","article-title":"Human papillomavirus in cancer: infection, disease transmission, and progress in vaccines","volume":"16","author":"Oyouni","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.vaccine.2025.127558_bb0140","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127558_bb0145","author":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2025.127558_bb0150","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/INF.0000000000003164","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine administered concomitantly or sequentially with quadrivalent human papillomavirus vaccine in boys and girls 9\u201313 years of age in Malaysia: a phase IIIb, randomized, open-label study","volume":"40","author":"Hassan","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127558_bb0155","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1016\/j.vaccine.2021.04.064","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico","volume":"39","author":"Arredondo","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127558_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00962-21","article-title":"Development and validation of two optimized multiplexed serologic assays for the 9-valent human papillomavirus vaccine types","volume":"8","author":"Nolan","year":"2023","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2025.127558_bb0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2025.127558_bb0170","doi-asserted-by":"crossref","first-page":"e1350","DOI":"10.1093\/cid\/ciac418","article-title":"Clinical safety experience of TAK-003 for dengue fever: a new tetravalent live attenuated vaccine candidate","volume":"76","author":"Patel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127558_bb0175","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127558_bb0180","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2025.127558_bb0185","author":"Thepgumpanat"},{"key":"10.1016\/j.vaccine.2025.127558_bb0190","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.vaccine.2013.12.037","article-title":"Systematic review of human papillomavirus vaccine coadministration","volume":"32","author":"Noronha","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127558_bb0195","doi-asserted-by":"crossref","first-page":"2161789","DOI":"10.1080\/21645515.2022.2161789","article-title":"Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis a vaccine: a phase 4, single-center, randomized, controlled trial","volume":"19","author":"Sun","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127558_bb0200","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127558_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106335","article-title":"National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects","volume":"144","author":"Tsu","year":"2021","journal-title":"Prev Med"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2025.127786","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:17:42Z","timestamp":1766546262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25008552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"alternative-id":["S0264410X25008552"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127558","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127558"}}